# US 2026/0216143 A1 · Pharmaceutical composition for treating chronic kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216143 A1
- Document ID: US20260216143A1
- Status: Published application
- Kind: A1
- Application number: 19/578,109
- Filed: 2026-03-25
- Published: 2026-07-30
- Earliest claimed: 2020-12-28
- Assignees: Cured Inc.
- Applicants: CURED Inc.
- Inventors: Masahiro MICHISHITA
- Web page: https://patentgrep.com/patent/US20260216143A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/232: having three or more double bonds, e.g. etretinate
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

For the object of establishing means for treating chronic kidney diseases including Alport syndrome, the present invention provides a pharmaceutical composition comprising a) a renin-angiotensin-system inhibitor and b) at least one type of an omega-3 polyunsaturated fatty acid, an ester thereof, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a triglyceride thereof.

## Claims

### Claim 1

A method of treating a chronic kidney disease which comprise administering to a patient in need thereof a pharmaceutical composition comprising a) a renin-angiotensin-system inhibitor and b) at least one type of an omega-3 polyunsaturated fatty acid, an ester thereof, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a triglyceride thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the chronic kidney disease is a kidney disease with glomerular damage.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the chronic kidney disease is a kidney disease with podocyte damage or a kidney disease with glomerular basement membrane damage.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the chronic kidney disease is a tubular kidney disease or an interstitial kidney disease.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the chronic kidney disease is Alport syndrome.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the renin-angiotensin-system inhibitor is an angiotensin II receptor antagonist.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the renin-angiotensin-system inhibitor is candesartan cilexetil.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the renin-angiotensin-system inhibitor is valsartan.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the at least one type of an omega-3 polyunsaturated fatty acid is eicosapentaenoic acid, docosahexaenoic acid, or eicosapentaenoic acid and docosahexaenoic acid.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the at least one type of an omega-3 polyunsaturated fatty acid is eicosapentaenoic acid and docosahexaenoic acid.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the at least one type of an omega-3 polyunsaturated fatty acid is docosahexaenoic acid.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the at least one type of an omega-3 polyunsaturated fatty acid is eicosapentaenoic acid.

### Claim 13 (depends on 1)

The method according to claim 1, wherein a) the renin-angiotensin system inhibitor and b) at least one type of the omega-3 polyunsaturated fatty acid, an ester thereof, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a triglyceride thereof are administered to the patient at different times.
